COPENHAGEN (Reuters) -Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday. Demand for Wegovy will be very high for the foreseeable future and higher than the Danish drugmaker can supply, Lars Fruergaard Jorgensen said in an interview after the company raised its full-year financial forecasts. Earlier on Thursday, the company said it would continue to restrict U.S. supplies of starter doses of Wegovy as the company strug...